Position in LLY
as of Jun 30, 2026
· filed Aug 4, 2026
Position Value
$11,055,147
+$301,425 QoQ
Shares Held
9,217
-34.6% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
43.07%
of 13F equity value
Holder Rank
#1,203
of 4,605 holders
Holding Since
Dec 2023
9 quarters on record
Voting authority
Sole 47%
Shared 0%
None 53%
Common Shares in LLY Over Time
Shares Held
Position Value (USD)
Derivatives in LLY
reported options exposure · as of Jun 30, 2026CallValue
$0
CallShares
0
PutValue
$5,397,435
PutShares
4,500
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Gimbal Financial holds $13,428,466 across 5 Drug Manufacturers - General names. LLY ranks #1 (82.3% of the industry book) .
All Filings in LLY
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $11,055,147 | 9,217 | Shares | Sole | 2026-08-04 | |
| 2026-06-30 | $5,397,435 | 4,500 | Put | Sole | 2026-08-04 | |
| 2025-09-30 | $10,753,722 | 14,094 | Shares | Sole | 2025-11-04 | |
| 2025-06-30 | $13,376,734 | 17,160 | Shares | Sole | 2025-07-30 | |
| 2025-03-31 | $14,862,250 | 17,995 | Shares | Sole | 2025-04-23 | |
| 2024-12-31 | $182,953 | 11,300 | Put | Sole | 2025-02-03 | |
| 2024-12-31 | $13,994,816 | 18,128 | Shares | Sole | 2025-02-03 | |
| 2024-09-30 | $16,060,320 | 18,128 | Shares | Sole | 2024-10-25 | |
| 2024-06-30 | $16,478,821 | 18,201 | Shares | Sole | 2024-07-12 | |
| 2024-03-31 | $14,481,725 | 18,615 | Shares | Sole | 2024-05-01 | |
| 2023-12-31 | $10,950,152 | 18,785 | Shares | Sole | 2024-02-01 | |
| No filing history on record for this holder in this stock. | ||||||